Following is a cumulative list of Hoosier Cancer Research Network publications in colorectal/rectal cancer.

Manuscripts and Journal Articles

• CJ Herting, MR Farren, Y Tong, Z Liu, B O’Neil, T Bekaii-Saab, A Noonan, C McQuinn, TA Mace, W Shaib, C Wu, BF El-Rayes, S Shahda, GB Lesinski. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy (2021): https://doi.org/10.1007/s00262-021-02986-5. See abstract.
• Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemother Pharmacol. 2012 Jul;70(1):25-32. doi: 10.1007/s00280-012-1883-1. Epub 2012 May 18.
• Cardenes, H., Sanghani, S., Burns, M., Robb, B., Hinkle, D., Johnson, C., Yu, M., Currie, C., Loehrer, P., Chiorean, E. Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC): A Hoosier Oncology Group Study GI03-53. International Journal of Radiation Oncology*Biology*Physics. Volume 78, Issue 3, Supplement, Page S54, 1 November 2010. doi:10.1016/j.ijrobp.2010.07.160
• Chong-Xian Pan MD, Ph.D, Patrick Loehrer MD, David Seitz MD, Paul Helft MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, and Christopher Sweeney MD. A Phase II Trial of Irinotecan, 5-Fluorouracil, Leucovorin, combined with Celecoxib and Glutamine as first line therapy for advanced colorectal cancer: Hoosier Oncology Group GI00-2. Oncology 2005;69:63-70.
• Bandealy M, Gonin R, Loehrer P, Monaco F, Einhorn L. A Prospective Randomized Trial of 5-Fluorouracil versus 5-Fluorouracil plus Levamisole in the Treatment of Metastatic Colorectal Cancer: Hoosier Oncology Group GI89-1. Clinical Cancer Research 4:935-939, 1998.
• Mantravadi RVP, Miller M, Ashley Lee J, Fisher W, Ansari R, Loehrer PJ: Prophylactic 32P Chromic Phosphate Therapy of the Liver in Completely Resected Modified Duke’s Stage C Colon Cancers: A Hoosier Oncology Group Study. In: Salmon, S. ed. Adjuvant Therapy of Cancer. 1990:446-453.
• Loehrer PJ, Turner S, Kubilis P, Hui S, Correa J, Ansari R, Stephens D, Woodburn R, Meyer S: A Prospective Randomized Trial of Fluorouracil Versus Fluorouracil plus Cisplatin in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group Trial. J Clin Oncol 6:642 48, 1988.

Abstracts, Posters, and Presentations

• Kristen R. Spencer, DO, MPH; Daniella E. Portal, BS; Christopher R. Heery, MD; Lynne M. Bauman, MS; Howard Hochster, MD; Elizabeth Poplin, MD; Usha Malhotra, MD; Richard B. Alexander, MD; David A. August, MD; Timothy Kennedy, MD; Miral Grandhi, MD; Russell C. Langan, MD; Edmund C. Lattime, PhD; Dirk F. Moore, PhD; Michael P. Kane, RPh, BCOP; Liesel Dudek, RN, OCN, CCRP; Sarah Nabeel; Darren Carpizo, MD, PhD. HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer. Presented as a Clinical Trials (In Progress) Poster at the Society for Immunotherapy of Cancer (SITC) 2018 Meeting, November 7-11, 2018. Journal for ImmunoTherapy of Cancer 2018 6 (Suppl 1):114. See abstract.
• Safi Shahda, Anne M. Noonan, Tanios S. Bekaii-Saab, Bert H. O’Neil, Amikar Sehdev, Walid Labib Shaib, Paul R. Helft, Patrick J. Loehrer, Yan Tong, Ziyue Liu, Bassel F. El-Rayes. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer (HCRN GI14-186). Accepted to Poster Session at the 2017 ASCO Annual Meeting. See abstract.
• Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618). See abstract.
• S. Shadha, M. Yu, J. Picus, J. Bufill, W. Harb, M. Burns, J. Spittler, J. Flynn, Y. Zeng, G. Vance, C. Currie, J. Wu, P. J. Loehrer, E.G. Chiorean. Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102, final report. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 3587)
• Chiorean EG, Schiel M, Sanghani S, Yu M, Shen J, Cardenes H, LeBlanc J, Robb B, Loehrer PJ, Harvey J: A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53. Poster Presentation at Indiana University Melvin and Bren Simon Cancer Center Cancer Research Day, May 7, 2008
• Chiorean EG, Schiel M, Sanghani S, Yu M, Shen J, Cardenes H, LeBlanc J, Robb B, Loehrer PJ, Harvey J: A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53. Accepted as Poster Presentation at the ASCO GI Symposium, January 25-27, 2008, Orlando, FL
• Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study GI00-2. Presented at the Glaxo/Smithkline National Oncology Fellows Forum, February 28-March 2, 2003, Miami, FL.
• Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study GI00-2. Accepted to the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• Christopher Sweeney MD, David Seitz MD, Rafat Ansari MD, William Pletcher MD, Naveed Chowhan MD, Jake Vinson MHA, Cindy Stoner BS; Patrick Loehrer MD; A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer: A Hoosier Oncology Group Study GI00-2. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL
• Bandealy MT, Gonin R, Loehrer PJ, Einhorn LH. A Prospective Randomized Hoosier Oncology Trial of 5-Fluorouracil versus 5-Fluorouracil Plus Levamisole in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial GI89-1. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.
• Mantravadi RVP, Miller M, Ashley Lee J, Fisher W, Ansari R, Loehrer PJ: Prophylactic 32P Chromic Phosphate Therapy of the Liver in Completely Resected Modified Duke’s Stage C Colon Cancers: A Hoosier Oncology Group Study. Presentation at Sixth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March l990. Proc Am Soc Clin Oncol 9:115, 1990
• Mantravadi RVP: Prophylactic 32P Chromic Phosphate Therapy of Liver in Completely Resected Colon Cancers Preliminary Results of a Phase III Study. Proc Amer Endocurie Therapy Society (l988).
• Loehrer PJ, Turner S, Kubilis P, Correa J, Ansari R, Einhorn LH, Williams SD, Stephens D, Woodburn R, Meyer S: A Prospective Randomized Study of 5-Fluorouracil Alone or with Cisplatin in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group Trial. Poster presentation at ASCO, Atlanta GA, May 1987. Proc Am Soc Clin Oncol 6:76, 1987.